Neupogen Archives - CDR – Chain Drug Review

Sandoz launches Zarxio, the nation’s first biosimilar

September 3, 2015 by John Schultz and Chain Drug Review Amgen, filgrastim, Neupogen, Novartis, Richard Francis, Sandoz, Sandoz One Source, Zarxio Leading Headlines, Pharmacy, Supplier News

NEW YORK — Sandoz has inaugurated a new era in medicine with the release of Zarxio, the first biosimilar of a biologic drug approved in the United States. The Novartis subsidiary said Thursday that Zarxio — a biosimilar of Amgen Corp.’s oncology drug Neupogen, which boosts white blood cells — would broaden access to an

Sandoz biosimilar receives backing of FDA panel

January 19, 2015 by John Schultz and Chain Drug Review biosimilar, cancer treatment, Center for Drug Evaluation and Research, FDA, Food and Drug Administration, Generic Pharmaceutical Association, Janet Woodcock, Johnson & Johnson, Merck, Neupogen, Neupogen biosimilar, Ralph Neas, Remicade, rheumatoid arthritis drug, Sandoz, Zarzio 2015, Issue 01-19-2015, News, Pharmacy

WASHINGTON — A Food and Drug Administration panel has recommended that the agency approve what could become the country’s first biosimilar. The panel unanimously urged approval of Sandoz’s filgrastin (Neupogen), a cancer treatment. “This encouraging step forward means that it is very likely now only a question of when, rather than if, filgrastin will be available